ALZA and Bio-Electro Systems
ALZA, a pharmaceutical company that has led the industry for over a decade, has been largely successful due to their unique technical innovation. Rather than specializing in discovering new drugs and treatments for medical conditions, ALZA instead focuses their pharmaceutical talents on developing new methods to deliver drugs to patients. From skin patches to time released capsules, ALZA captures their market by providing their technologies to all major pharmaceutical companies, in return charging royalties that has led the company to realize immense consecutive profits. However, drug delivery technologies are constantly evolving, which has caused more effective and efficient methods to appear at a rapid rate. While ALZA is a leader in its industry, it needs to invest in advancing their own technologies if it wants to enjoy its current state of profitability, growth, and leadership. To implement this effort of advancing its drug delivery technologies, Martin Gerstel, CEO of ALZA, approved a 40 million dollar proposal to aid in developing its technologies. Yet, the solution wasn't nearly as simple as they had hoped, the company still needed to develop a method of organizing and paying for the 40 million dollar project. The company came up with three options: a.
Utilization of ALZA's own assets to finance the new venture b.
Partnership with a leading pharmaceutical company to establish a joint venture c.
Establishing a partly owned Research and Development organization funded by both ALZA and investors in equity The first option is the most obvious method that has been utilized by many companies before ALZA, however it is not the most financially efficient method for ALZA to implement. By utilizing their own assets, their balance sheet will be severely impacted on the right side, which could cause a massive negative impact on the company's stock price. Many don't realize that a decrease in a company's equity price will ultimately...
Please join StudyMode to read the full document